Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules that activate telomerase reverse transcriptase (TERT), an enzyme that plays a major role in preventing cellular senescence. The companys mission is to develop drugs to delay the onset and the progression of neurodegenerative diseases such as ALS and to improve and extend patients lives. Neuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis).